Supernus Pharmaceuticals, Inc. announced a proposed merger of equals with Indivior Pharmaceuticals Inc., creating a leading U.S. biopharmaceutical company focused on central nervous system diseases. The all-stock transaction is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals. Jack A. Khattar will serve as CEO of the combined entity. The merged company will combine Supernus's franchises (Qelbree, Zurzuvae, Onapgo, Gocovri) with Indivior's (Sublocade, Suboxone), generating approximately $2.16 billion in trailing twelve-month net revenue as of June 30, 2026. The filing references a Special Dividend funded by additional indebtedness to be incurred by the combined company. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system disorders.

Supernus Pharmaceuticals announced a proposed merger of equals with Indivior on August 3, 2026. The transaction is structured as a 100% tax-free stock-for-stock exchange where Supernus shareholders will receive 1.5401 Indivior shares for each share held. Prior to closing, Indivior intends to declare an aggregate special cash dividend of $1 billion to its pre-closing stockholders. The combined entity is projected to generate approximately $2.2 billion in pro forma net revenues and achieve at least $125 million in annual cost synergies. Supernus shareholders are expected to hold 43.5% ownership, with Jack Khattar serving as CEO of the new company headquartered in Rockville, Maryland. The deal targets a Q4 2026 closing subject to shareholder and regulatory approvals. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system disorders.

Supernus Pharmaceuticals reported second quarter 2026 total revenues of $219.1 million, a 32% increase year-over-year, driven by strong growth in its four key products: Qelbree ($89.2 million), GOCOVRI ($37.6 million), ONAPGO ($13.5 million), and ZURZUVAE collaboration revenue ($35.4 million). The company raised its full year 2026 financial guidance, projecting total revenues between $860 million and $890 million and adjusted operating earnings of $150 million to $180 million. Supernus also announced a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock merger of equals, creating a diversified central nervous system biopharmaceutical company. The combined entity aims to leverage scale and growth opportunities across the CNS therapeutic space.

On August 1, 2026, Supernus Pharmaceuticals entered into a definitive merger agreement with Indivior Pharmaceuticals to combine in a tax-free all-stock transaction valued as a merger of equals. Upon closing, Supernus shareholders will receive 1.5401 shares of Indivior stock for each share held, resulting in an ownership split where Indivior stockholders own approximately 56.5% and Supernus stockholders own 43.5% of the combined entity, which will retain the name Supernus, Inc. and ticker symbol SUPN. The transaction includes a $1 billion special cash dividend for Indivior shareholders, funded by a $650 million senior secured term loan from Citibank and existing cash reserves. Jack A. Khattar will serve as CEO of the combined company, with Tony Kingsley as Board Chair. Expected annual cost synergies total $125 million against pro forma net revenues of $2.2 billion. The deal is subject to stockholder approvals, regulatory clearance including Hart-Scott-Rodino, and customary closing conditions, with a target close in the fourth quarter of 2026. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system diseases.

Supernus Pharmaceuticals, Inc. announced that it will report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026, and will host a conference call and webcast to discuss the results. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.